[HTML][HTML] The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung …
L Wang, Z He, S Yang, H Tang, Y Wu, S Li… - Translational Lung …, 2019 - ncbi.nlm.nih.gov
Background Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer …
L Wang, Z He, S Yang, H Tang, Y Wu… - Translational lung …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
[PDF][PDF] The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung …
L Wang, Z He, S Yang, H Tang, Y Wu, S Li, B Han, K Li… - cdn.amegroups.cn
Background: Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer …
L Wang, Z He, S Yang, H Tang, Y Wu, S Li… - Translational Lung …, 2019 - europepmc.org
Background Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer …
L Wang, Z He, S Yang, H Tang, Y Wu… - Translational Lung …, 2019 - tlcr.amegroups.org
Background: Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer …
L Wang, Z He, S Yang, H Tang, Y Wu, S Li… - Translational Lung …, 2019 - europepmc.org
Background Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
[HTML][HTML] The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung …
L Wang, Z He, S Yang, H Tang, Y Wu… - Translational Lung …, 2019 - tlcr.amegroups.org
Background: Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …